Centre Regional De Transfusion Sanguine De Lille

Association Pour L'essor De La Transfusion Sanguine Dans La Region Du

Miryana Burnouf-Radosevich

Thierry Burnouf

Dominique Dernis

Patrick Bonneel

Immunoglobulin G concentrate for therapeutic use and process for

The invention relates to a process for preparing a concentrate of Factor VIII-von Willebrand factor complex having high specific activity from total (non-cryoprecipitated) plasma. The process comprises pre-purifying by means of a double treatment with barium chloride and with aluminium hydroxide. The process then comprises purification by chromatography on an anion exchange resin, of the DEAE-Fractogel type. The process includes a step of viral inactivation by means of a treatment with solvent-detergent. The process also makes it possible to recover fibrinogen, albumin, immunoglobulins, antithrombin III, fibronectin and prothrombin complex, from the same plasma. The different concentrates obtained using the process according to the invention are intended, in particular, for therapeutic use.

Process for preparing a concentrate of blood coagulation factor VIII-von

The invention relates to a process for purifying human von Willebrand factor from a cryoprecipitated plasma fraction, which comprises a combination of three chromatographic separation steps. The first chromatographic separation step comprises contacting a cryoprecipitated fraction with a large-pore vinyl polymer resin having DEAE group. The effluent from this separation step is again contacted with a large pore vinyl polymer resin having DEAE groups in the second chromatographic step. In the third chromatographic separation step, the effluent from the second step is subjected to affinity chromatography by contacting with gelatin-Sepharose. The concentrate obtained has very high specific activity and a high percentage of high molecular weight multimers. The concentrate is intended, in particular, for therapeutic use.

Process for an industrial-scale preparation of a standardized human von

The invention provides a thrombin coagulable protein concentrate,, the preparation thereof and the therapeutic use thereof. This concentrate has a fibrinogen content greater than 70% and a sufficient amount of endogenous Factor XIII. It may be solubilized at ambient temperature. Its preparation comprises at least one cold precipitation step with dilute ethanol and uses total plasma as a starting product. The concentrate of the invention makes it possible more particularly to obtain an injectable fibrinogen and a biological glue of high quality.

Concentrate of thrombin coagulable proteins, the method of obtaining

The invention relates to a human Factor XI concentrate having high specific activity prepared using a process comprising a filtration-adsorption step and a single step of chromatography on cation exchange resin. The concentrate obtained is perfectly suitable for therapeutic use in replacement therapy in cases of Factor XI deficiency.

Growing community of inventors

Wavrin, France

Miryana Burnouf-Radosevich